|
News and Press Releases from StemCyte®, Inc. | |||
|
|
February 26, 2008
StemCyte Expands Support of World Renowned Spinal Cord Injury Researcher Through Agreement with Rutgers UniversityStemCyte, Rutgers Sign Research, Licensing Agreement for Novel Human Umbilical Cord Blood Treatment for Spinal Cord Injury Being Developed by Wise Young, M.D., Ph.D. StemCyte Inc. and Rutgers, The State University of New Jersey, today announced at the Stem Cell Summit that they have entered into a research and licensing agreement for a spinal cord injury therapy being developed by Wise Young, M.D., Ph.D., that uses StemCyte’s proprietary human umbilical cord blood (UCB) stem cells in conjunction with lithium. |
StemCyte has now provided cord blood units to over 130 transplant centers worldwide across 6 continents, and the number of units released for transplantation is rapidly increasing. | ||
February 26, 2008
StemCyte to Present Overview of Company and its Umbilical Cord Blood Stem Cell Therapies at 3rd Annual Stem Cell SummitWorld-Renowned Spinal Cord Injury Researcher and StemCyte Collaborator Wise Young to Participate in Presentation by Company’s Chairman StemCyte Inc. today announced that Kenneth J. Giacin, chairman and chief executive officer, will present an overview of the company and its marketed umbilical cord blood stem cell therapies today at the 3rd Annual Stem Cell Summit in New York City. |
||||
February 21, 2008
StemCyte Presents Six Abstracts on the Applications of Plasma-Depleted Umbilical Cord Blood Stem Cell Products at BMT Tandem MeetingsThe benefits of plasma-depleted cord blood stem cell products were the subjects of six abstracts presented this week by StemCyte, Inc. and collaborators at the Bone Marrow Transplant (BMT) Tandem Meetings in San Diego. |
||||
November 8, 2007
Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award from the National Marrow Donor ProgramDr. Auayporn Nademanee of City of Hope leads study showing efficacy of novel therapy The National Marrow Donor Program (NMDP) has selected an abstract written by Dr. Auayporn Nademanee, physician and professor in the Division of Hematology & Hematopoietic Cell Transplantation at City of Hope, and Dr. Robert Chow, Founder and Global Medical Director for StemCyte, as one of four best abstracts at its annual Council Meeting in Minneapolis, MN. |
||||
October 3, 2007
StemCyte®, Inc. Ranked Number Six in Deloitte's Technology Fast 50 Program for Los AngelesIncreasing Acceptance of Umbilical Cord Blood Stem Cells as a Curative Therapy Driving GrowthStemCyte, Inc. has been named to Deloitte's prestigious Technology Fast 50 Program for Los Angeles, a ranking of the 50 fastest growing technology, media, telecommunications, and life sciences companies in the area by Deloitte & Touche USA LLP, one of the nation's leading professional services organizations. Rankings are based on the percentage revenue growth over five years from 2002-2006. |
||||
July 11, 2007
StemCyte®, Inc. Appoints Robert Dickey IV as Senior Vice President and Chief Financial OfficerStemCyte, Inc., a leading stem cell transplantation and therapeutics company, announced today the appointment of Robert Dickey IV as Senior Vice President and Chief Financial Officer. Mr. Dickey brings to StemCyte a total of more than 25 years of experience in entrepreneurial management and in investment banking. During his career, Mr. Dickey has been actively involved in fundraising in both the private and public markets, IPO's, and mergers and acquisitions. In addition, he has significant experience in the building and management of high growth companies. He will be based with StemCyte's CEO, CSO and head of business development, among others, at the Company's planned new headquarters on the east coast. |
||||
April 16, 2007
StemCyte®, Inc. Releases its 500th Cord Blood Stem Cell Shipment for TransplantStemCyte, Inc. recently released its 500th cord blood stem cell shipment for transplant. This marks another milestone in the company's rapid growth as one of the world's leading providers of quality cord blood stem cell products. StemCyte has now provided cord blood stem cell shipments to over 130 transplant centers worldwide across 6 continents, with the number of shipments released for transplantation increasing rapidly. StemCyte's therapeutic products have been used for the treatment of over 40 diseases, including leukemias, lymphomas, immune diseases and genetic disorders. |
||||
November 3, 2006
StemCyte®, Inc. Receives Contract from Federal Government to Help Build National Cord Blood Inventory for United StatesThe Health Resource Service Administration (HRSA) announced today that StemCyte, Inc. has been selected to help build a national inventory of 150,000 cord blood units under the C.W. Bill Young Cell Transplantation Program. The awards were the first such disbursement of the $79 million authorized by Congress in the Stem Cell Therapeutic and Research Act of 2005 and signed into law by President Bush. HRSA selected StemCyte as one of six cord blood banks in the country from a competitive proposal process. |
||||
|
October 24, 2006 Dr. Lawrence Petz, Chief Medical Officer at Stemcyte®, Inc., receives Tibor Greenwalt Memorial Award and LectureshipThe AABB announced that Lawrence D. Petz, MD, chief medical officer at StemCyte, Inc., received the Tibor Greenwalt Memorial Award and Lectureship for 2006. According to the AABB, "This award recognizes an individual who made major scientific or clinical contributions to hematology and transfusion medicine and succinctly communicated these advances." Dr. Petz received the award at the AABB annual meeting in Miami, FL, which ends today. |
||||
|
May 4, 2006 Stemcyte®, Inc. surpasses 300th cord blood unit shipped for transplantStemCyte, Inc., a privately held stem cell therapy and cord blood bank, with highly accredited processing and storage facilities in both the U.S. and Taiwan, recently shipped its 300th cord blood stem cell unit for transplant. This marks another milestone in the company's rapid growth as one of the world's leading providers of quality cord blood stem cell units. StemCyte has now provided cord blood units to over 95 transplant centers worldwide across 5 continents, with the number of units released for transplantation increasing rapidly. StemCyte's units have been used for the treatment of over 40 diseases, including leukemias, lymphomas, immune diseases and genetic disorders. |
||||
|
May 1, 2006 Stemcyte®, Inc. receives accreditation from Foundation for the Accreditation of Cellular TherapyStemCyte, Inc., a privately held stem cell therapy and cord blood bank, has received accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) for its International Cord Blood Center in Arcadia, California. This accreditation means that the StemCyte International Cord Blood Center is now among a handful of cord blood banks to receive accreditation from the American Association of Blood Banks (AABB), the National Marrow Donor Program (NMDP), the College of American Pathologists (CAP), and Foundation for the Accreditation of Cellular Therapy (FACT) for allogeneic donations. The StemCyte International Cord Blood Center is now the first and the only cord blood bank in the world accredited by FACT for autologous donations. |
||||
January 23, 2006
StemCyte®, Inc. surpasses 250th cord blood stem cell transplantStemCyte, Inc., a privately held stem cell therapy and cord blood bank, with highly accredited processing and storage facilities in both the U.S. and Taiwan, recently contributed its 250th cord blood stem cell unit for transplant. This marks another milestone in the company's rapid growth as one of the world's leading providers of quality cord blood stem cell units. StemCyte has now provided cord blood units to over 80 transplant centers worldwide across 5 continents, with the number of units released for transplantation is rapidly increasing. |
||||
|
January 12, 2006 New study confirms prior research showing efficacy of using umbilical cord blood to treat Thalassemia patientsStemCyte, Inc. and International Experts Gather To Review Latest Advances in Blood-borne Disease Arcadia, CA (January 12, 2006)- StemCyte, Inc., a leading, global umbilical cord blood (UCB) stem cell transplantation and therapeutic products company, today announced that a new study has confirmed prior research suggesting that unrelated UCB transplants may be a promising and cost-effective approach for curative therapy of thalassemia. Approximately 150,000 children worldwide are born each year with a serious form of thalassemia that could be cured by UCB transplants that StemCyte has helped to pioneer. |
||||
|
July 27, 2005 StemCyte®, Inc. Surpasses 200th Cord Blood Stem Cell Transplant Leading Breakthrough Clinical Study for Thalassemia in TaiwanARCADIA, Calif., July 26 /PRNewswire/ -- StemCyte, Inc., a privately held stem cell therapy and cord blood bank, contributed its 200th cord blood unit for transplant last month, marking another milestone in the company's growth as one of the world's leading providers of quality cord blood stem cell units. StemCyte has now provided cord blood units to over 80 transplant centers worldwide across 5 continents, and the number of units released for transplantation is rapidly increasing. |
||||
|
July 19, 2005 StemCyte, Inc., Completes Significant Round of FinancingStemCyte(R), Inc., a leading umbilical cord blood stem cell transplantation and therapeutic products company, today announced it has recently completed a significant round of financing from new investors within both the United States and abroad. StemCyte sold approximately $13.7MM of new securities. |
||||
|
July 1, 2005 Cord Blood In The NewsDuring the past 18 months, there has been a flurry of media activity related to cord blood stem cell banking and transplantation. Most importantly, the emerging acceptance of transplant physicians to use cord blood stem cell transplants to address the lion share of the major unmet medical need, adult patients, is by far the most exciting development. |
||||
 |
|
